* Antiemetic. Treatment of vomiting and nausea. Prokinetic action. Breakable tablets.
* Composition: Each tablet contains:
& & Metoclopramide hydrochloride 10.5 mg Equivalent to Metoclopramide hydrochloride anhydrous 10 mg.
* Therapeutic indications:
& & Symptomatic treatment of nausea and vomiting including delayed nausea and vomiting induced by antimitotic agents.
* Dosage and administration:
& & – Reserved for adults and children over 20 kg (i.e. about 6 years old) only.
& & – Nausea and vomiting:
& & Adults: 1/2 to 1 tablet, 3 times daily, before meals, with an interval of 6 hours between intakes.
& & In this indication, this dosage is not suitable for children.
& & – Delayed nausea and vomiting induced by certain treatments:
& & Adults and children weighing more than 20 kg: 0.5 mg / kg, 4 times daily, i.e. 1 tablet per 20 kg of bodyweight per dose.
& & – Route of administration: oral route.
& & – Frequency and time of administration: Leave an interval of at least 6 hours between doses.
* Contraindications:
& & – Hypersensitivity to metclopramide or any of the components.
& & – If stimulation of gastrointestinal motility is hazardous to the patient: in the event of gastrointestinal
& & bleeding, mechanical obstruction or gastrointestinal perforation.
& & – In patients having previously presented with tardive dyskinesia induced by neuroleptics or metoclopramide.
& & – In patients with known or suspected pheochromocytoma (apart from as a provocative test);
& & serious hypertensive events have been reported with dopamine antagonists including certain
& & benzamides in this patient category,
& & – In combination with dopamine agonists and selegline.
& & – Known history of methemoglobinemia with metoclopramide or NADH-cytochrome b5 reductase
& & deficiency.
* Special warning and precautions for use:
& & # Special warnings:
& & – Only the oral drop form is suitable for infants.
& & – Neurological undesirable effects (extrapyramidal syndrome) may develop, particularly in children
& & and in young adults.
& & – Since neuroleptic malignant syndrome has been reported in exceptional cases, treatment must be
& & immediately discontinued in the event of unexplained hyperthermia or hyperthermia associated with
& & other symptoms of malignant syndrome (pallor, vegetative disorders, impaired consciousness,
& & muscular rigidity).
& & – In the event of vomiting, or partial/complete rejection of the dose administered, maintain the stipulated
& & dosing interval before readministering the medicinal product.
& & – In the event of profuse vomiting, it is essential to guard against dehydration. The patient may be
& & rehydrated orally using “sweet-saline” solutions (oral rehydration solutions) given in small quantaties
& & at regular intervals.
& & – Cases of methemoglobinemia, possibly due to NADH-cytochrome b5 reductase deficiency, have been
& & reported. In such an event, treatment must be immediately and definitively discontinued, and appropriate
& & measures implemented.
& & – Due to the presence of lactose, this medicinal product is contraindicated in the event of congenital
& & galactosemia, glucose/galactose malabsorption syndrome or lactose deficiency.
& & # Sepcial precuations for use:
& & – Use of this medicinal product is not recommended in epileptic patients (increased frequency and intensity
& & of fits).
& & – In the event of renal or hepatic impairment, it is advisable to reduce the dosage.
* Pregnancy and lactation:
& & – Metoclopramide should be be used only if needed during pregnancy.
& & – Metoclopramide passes into breast milk. In consequence, breast-feeding should be avoided.
& & Breast-feeding is not recommended in the event of premature birth or high-dose treatment.
* Effects on ability to drive and use machines:
& & Drivers and machine operators must be made aware of the risk of drowsiness related to
& & use of the medicinal product.
* Contraindication in children less than 18 years.
* Not to be used without medical supervision.
* Store at temperature not exceeding 30 degrees C, in a dry place.
* Produced by: sanofi-aventis Egypt s.a.e. Under license of: sanofi-aventis – France.
* Barcode: 6223003991128 (same as that for: PRIMPERAN 10 MG 20 TAB).
Weight | 100 kg |
---|
Q & A
Ask a question
Your question will be answered by a store representative or other customers.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Thank you for the question!
Your question has been received and will be answered soon. Please do not submit the same question again.
Error
An error occurred when saving your question. Please report it to the website administrator. Additional information:
Add an answer
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Thank you for the answer!
Your answer has been received and will be published soon. Please do not submit the same answer again.
Error
An error occurred when saving your answer. Please report it to the website administrator. Additional information:
2 reviews for PRIMPERAN 10 MG 10 TAB